Journals / MN Oftalmoloji / 2001 / Cilt: 8 - Sayı: 2

The effect of dorzolamide on central corneal thickness in patients with prior intraocular surgery

Göziçi cerrahisi geçiren gözlerde dorzolamidin santral kornea kalınlığı üzerine etkisi

Pages
153–155
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSIONS: Dorzolamide did not effect the central corneal thickness in patients with a history of intraocular surgery which might compromise corneal endothelial function.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To determine the effect of dorzolamide hydrochlorur ophthalmic solution, a topical carbonic anhydrase enzyme inhibitor, on the central corneal thickness in patients with prior intraocular surgery.
📊
Key Findings & Data:MATERIAL AND METHODS: Sixteen cases (23 eyes) with a history of intraocular surgery were included in this study.
💡
Conclusion & Impact:CONCLUSIONS: Dorzolamide did not effect the central corneal thickness in patients with a history of intraocular surgery which might compromise corneal endothelial function.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Oftalmolojik cerrahi işlemler · Kornea · Oftalmik solüsyonlar

Abstract

PURPOSE: To determine the effect of dorzolamide hydrochlorur ophthalmic solution, a topical carbonic anhydrase enzyme inhibitor, on the central corneal thickness in patients with prior intraocular surgery. MATERIAL AND METHODS: Sixteen cases (23 eyes) with a history of intraocular surgery were included in this study. Dorzolamide was combined to other antiglaucomatous drugs in 16 eyes (69.5%) and it was given as a monotherapy in 7 eyes (30.5%). Central corneal thickness and intraocular pressure measurements were performed before the treatment and at the 4th and 12th weeks of the treatment. RESULTS: The intraocular pressure levels decreased significantly at 4th and 12th weeks of dorzolamide therapy (p=0.000) and there was an increase in the central corneal thickness measurements which was not statistically significant (p=0.205). CONCLUSIONS: Dorzolamide did not effect the central corneal thickness in patients with a history of intraocular surgery which might compromise corneal endothelial function.

Özet

AMAÇ: Topikal karbonik anhidraz enzim inhibitörü dorzolamid hidroklorür oftalmik solüsyonunun göziçi cerrahisi geçiren gözlerde santral kornea kalınlığı üzerindeki etkisini değerlendirmek. GEREÇ VE YÖNTEM: Göziçi cerrahisi uygulanan 16 olgunun 23 gözü çalışma kapsamına alındı. Dorzolamid 16 gözde (%69.5) diğer antiglokomatöz ilaçlarla kombine 7 olguda (%30.5) ise monoterapi olarak uygulandı.Olgularda tedavi öncesi ve dorzolamid tedavisinin 4. ve 12. haftalarında santral kornea kalınlığı ve göziçi basıncı ölçümleri yapıldı. BULGULAR: Dorzolamidin 4 hafta ve 12 hafta klinik uygulanımının göziçi basıncını istatistiksel olarak anlamlı derecede azalttığı (p=0.000), santral kornea kalınlığında ise istatistiksel olarak anlamlı olmayan bir artışa neden olduğu belirlendi (p=0.205). SONUÇ: Kornea endotel fonksiyonunun geçirilen göziçi cerrahisine bağlı olarak etkilenebileceği düşünülen olgularda, dorzolamid uygulanımının santral kornea kalınlığını etkilemediği belirlendi.

🔖

Cite This Article

DEMİRBAY, D. P., KOÇ, F., ERDİNÇ, E., ASYALI, A., YARPUZ, İ. M., TUNA, T., URAL, F., FIRAT, E. (2001). The effect of dorzolamide on central corneal thickness in patients with prior intraocular surgery. MN Oftalmoloji, Cilt: 8 - Sayı: 2, 153–155. https://ajindex.com/articles/296322